# Development of Medical Countermeasures for COVID-19

> **NIH NIH N01** · BIOCRYST PHARMACEUTICALS, INC. · 2021 · $1,383,666

## Abstract

This contract supports the advanced development of promising therapeutic candidates with broad spectrum activity. The research and development activities to be supported will allow candidate therapeutic products to progress through the product development pipeline, and includes preclinical and non-clinical activities, as well as IND development activities.

## Key facts

- **NIH application ID:** 10490798
- **Project number:** 272201300017C-P00025-9999-1
- **Recipient organization:** BIOCRYST PHARMACEUTICALS, INC.
- **Principal Investigator:** RAYMOND TAYLOR
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,383,666
- **Award type:** —
- **Project period:** 2020-08-11 → 2022-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10490798

## Citation

> US National Institutes of Health, RePORTER application 10490798, Development of Medical Countermeasures for COVID-19 (272201300017C-P00025-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10490798. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*